Copyright Reports & Markets. All rights reserved.

Global Anti-Inflammatory Peptides Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Anti-Inflammatory Peptides

      • 1.1 Definition of Anti-Inflammatory Peptides
      • 1.2 Anti-Inflammatory Peptides Segment by Type
        • 1.2.1 Global Anti-Inflammatory Peptides Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Cardiovascular Diseases
        • 1.2.3 Gastrointestinal Diseases
        • 1.2.4 Dermatological Diseases
        • 1.2.5 Neurological Diseases
        • 1.2.6 Otorhino Diseases & Ophthalmological
        • 1.2.7 Respiratory Diseases & Pulmonary
        • 1.2.8 Renal Diseases
        • 1.2.9 Rheumatological & Autoimmune Diseases
        • 1.2.10 Transplantation
      • 1.3 Anti-Inflammatory Peptides Segment by Applications
        • 1.3.1 Global Anti-Inflammatory Peptides Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospital Use
        • 1.3.3 Clinic Use
        • 1.3.4 Household
        • 1.3.5 Other
      • 1.4 Global Anti-Inflammatory Peptides Overall Market
        • 1.4.1 Global Anti-Inflammatory Peptides Revenue (2014-2025)
        • 1.4.2 Global Anti-Inflammatory Peptides Production (2014-2025)
        • 1.4.3 North America Anti-Inflammatory Peptides Status and Prospect (2014-2025)
        • 1.4.4 Europe Anti-Inflammatory Peptides Status and Prospect (2014-2025)
        • 1.4.5 China Anti-Inflammatory Peptides Status and Prospect (2014-2025)
        • 1.4.6 Japan Anti-Inflammatory Peptides Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Anti-Inflammatory Peptides Status and Prospect (2014-2025)
        • 1.4.8 India Anti-Inflammatory Peptides Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Anti-Inflammatory Peptides
      • 2.3 Manufacturing Process Analysis of Anti-Inflammatory Peptides
      • 2.4 Industry Chain Structure of Anti-Inflammatory Peptides

      3 Development and Manufacturing Plants Analysis of Anti-Inflammatory Peptides

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Anti-Inflammatory Peptides Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Anti-Inflammatory Peptides
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Anti-Inflammatory Peptides Production and Capacity Analysis
      • 4.2 Anti-Inflammatory Peptides Revenue Analysis
      • 4.3 Anti-Inflammatory Peptides Price Analysis
      • 4.4 Market Concentration Degree

      5 Anti-Inflammatory Peptides Regional Market Analysis

      • 5.1 Anti-Inflammatory Peptides Production by Regions
        • 5.1.1 Global Anti-Inflammatory Peptides Production by Regions
        • 5.1.2 Global Anti-Inflammatory Peptides Revenue by Regions
      • 5.2 Anti-Inflammatory Peptides Consumption by Regions
      • 5.3 North America Anti-Inflammatory Peptides Market Analysis
        • 5.3.1 North America Anti-Inflammatory Peptides Production
        • 5.3.2 North America Anti-Inflammatory Peptides Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Anti-Inflammatory Peptides Import and Export
      • 5.4 Europe Anti-Inflammatory Peptides Market Analysis
        • 5.4.1 Europe Anti-Inflammatory Peptides Production
        • 5.4.2 Europe Anti-Inflammatory Peptides Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Anti-Inflammatory Peptides Import and Export
      • 5.5 China Anti-Inflammatory Peptides Market Analysis
        • 5.5.1 China Anti-Inflammatory Peptides Production
        • 5.5.2 China Anti-Inflammatory Peptides Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Anti-Inflammatory Peptides Import and Export
      • 5.6 Japan Anti-Inflammatory Peptides Market Analysis
        • 5.6.1 Japan Anti-Inflammatory Peptides Production
        • 5.6.2 Japan Anti-Inflammatory Peptides Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Anti-Inflammatory Peptides Import and Export
      • 5.7 Southeast Asia Anti-Inflammatory Peptides Market Analysis
        • 5.7.1 Southeast Asia Anti-Inflammatory Peptides Production
        • 5.7.2 Southeast Asia Anti-Inflammatory Peptides Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Anti-Inflammatory Peptides Import and Export
      • 5.8 India Anti-Inflammatory Peptides Market Analysis
        • 5.8.1 India Anti-Inflammatory Peptides Production
        • 5.8.2 India Anti-Inflammatory Peptides Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Anti-Inflammatory Peptides Import and Export

      6 Anti-Inflammatory Peptides Segment Market Analysis (by Type)

      • 6.1 Global Anti-Inflammatory Peptides Production by Type
      • 6.2 Global Anti-Inflammatory Peptides Revenue by Type
      • 6.3 Anti-Inflammatory Peptides Price by Type

      7 Anti-Inflammatory Peptides Segment Market Analysis (by Application)

      • 7.1 Global Anti-Inflammatory Peptides Consumption by Application
      • 7.2 Global Anti-Inflammatory Peptides Consumption Market Share by Application (2014-2019)

      8 Anti-Inflammatory Peptides Major Manufacturers Analysis

      • 8.1 Mylan Pharmaceuticals
        • 8.1.1 Mylan Pharmaceuticals Anti-Inflammatory Peptides Production Sites and Area Served
        • 8.1.2 Mylan Pharmaceuticals Product Introduction, Application and Specification
        • 8.1.3 Mylan Pharmaceuticals Anti-Inflammatory Peptides Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Novartis AG
        • 8.2.1 Novartis AG Anti-Inflammatory Peptides Production Sites and Area Served
        • 8.2.2 Novartis AG Product Introduction, Application and Specification
        • 8.2.3 Novartis AG Anti-Inflammatory Peptides Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Rogne Bioscience
        • 8.3.1 Rogne Bioscience Anti-Inflammatory Peptides Production Sites and Area Served
        • 8.3.2 Rogne Bioscience Product Introduction, Application and Specification
        • 8.3.3 Rogne Bioscience Anti-Inflammatory Peptides Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Merck Serono
        • 8.4.1 Merck Serono Anti-Inflammatory Peptides Production Sites and Area Served
        • 8.4.2 Merck Serono Product Introduction, Application and Specification
        • 8.4.3 Merck Serono Anti-Inflammatory Peptides Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 F4 Pharma
        • 8.5.1 F4 Pharma Anti-Inflammatory Peptides Production Sites and Area Served
        • 8.5.2 F4 Pharma Product Introduction, Application and Specification
        • 8.5.3 F4 Pharma Anti-Inflammatory Peptides Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Araim Pharmaceuticals, Inc.
        • 8.6.1 Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Production Sites and Area Served
        • 8.6.2 Araim Pharmaceuticals, Inc. Product Introduction, Application and Specification
        • 8.6.3 Araim Pharmaceuticals, Inc. Anti-Inflammatory Peptides Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Digna Biotech
        • 8.7.1 Digna Biotech Anti-Inflammatory Peptides Production Sites and Area Served
        • 8.7.2 Digna Biotech Product Introduction, Application and Specification
        • 8.7.3 Digna Biotech Anti-Inflammatory Peptides Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Abbvie Corporation
        • 8.8.1 Abbvie Corporation Anti-Inflammatory Peptides Production Sites and Area Served
        • 8.8.2 Abbvie Corporation Product Introduction, Application and Specification
        • 8.8.3 Abbvie Corporation Anti-Inflammatory Peptides Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served

      9 Development Trend of Analysis of Anti-Inflammatory Peptides Market

      • 9.1 Global Anti-Inflammatory Peptides Market Trend Analysis
        • 9.1.1 Global Anti-Inflammatory Peptides Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Anti-Inflammatory Peptides Regional Market Trend
        • 9.2.1 North America Anti-Inflammatory Peptides Forecast 2019-2025
        • 9.2.2 Europe Anti-Inflammatory Peptides Forecast 2019-2025
        • 9.2.3 China Anti-Inflammatory Peptides Forecast 2019-2025
        • 9.2.4 Japan Anti-Inflammatory Peptides Forecast 2019-2025
        • 9.2.5 Southeast Asia Anti-Inflammatory Peptides Forecast 2019-2025
        • 9.2.6 India Anti-Inflammatory Peptides Forecast 2019-2025
      • 9.3 Anti-Inflammatory Peptides Market Trend (Product Type)
      • 9.4 Anti-Inflammatory Peptides Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Anti-Inflammatory Peptides Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Anti-inflammatory peptides also known as antiflammins inhibit inflammation of a mammal\'s skin, lacerations of the musculature, mucous membranes, or injury into the air spaces of the lungs. Anti-inflammatory peptides act by hindering synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions. Anti-Inflammatory peptides are used to treat diseases such as psoriasis, multiple sclerosis, inflammatory bowel disease and other autoimmune diseases.
        North America has dominated the entire market in 2014, as it has presence of technologically updated systems, strong research & development, and high patient awareness levels in this region. Latin America is also expected to grow at a healthy rate as a result of increase in both private and public associations, causing an increase in the investment, thereby boosting the demand for the anti-inflammatory peptides. However, the Asia Pacific region is expected to witness lucrative growth during the forecast period owing to the rapidly improving healthcare infrastructure in the growing economies of India and China. Growing patient awareness levels among the population of this region coupled with high unmet needs of the patients is expected to further drive this region.

        The global Anti-Inflammatory Peptides market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Anti-Inflammatory Peptides volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-Inflammatory Peptides market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Anti-Inflammatory Peptides in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Anti-Inflammatory Peptides manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Mylan Pharmaceuticals
        Novartis AG
        Rogne Bioscience
        Merck Serono
        F4 Pharma
        Araim Pharmaceuticals, Inc.
        Digna Biotech
        Abbvie Corporation

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Cardiovascular Diseases
        Gastrointestinal Diseases
        Dermatological Diseases
        Neurological Diseases
        Otorhino Diseases & Ophthalmological
        Respiratory Diseases & Pulmonary
        Renal Diseases
        Rheumatological & Autoimmune Diseases
        Transplantation

        Segment by Application
        Hospital Use
        Clinic Use
        Household
        Other

        Buy now